Terms: = Germ cell tumor AND FUBP1, FBP, 8880, ENSG00000162613, FUBP
56 results:
1. Genomic alterations of oligodendrogliomas at distant recurrence.
Liu G; Bu C; Guo G; Zhang Z; Sheng Z; Deng K; Wu S; Xu S; Bu Y; Gao Y; Wang M; Liu G; Kong L; Li T; Li M; Bu X
Cancer Med; 2023 Aug; 12(16):17171-17183. PubMed ID: 37533228
[TBL] [Abstract] [Full Text] [Related]
2. Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis.
Lee K; Kim SI; Kim EE; Shim YM; Won JK; Park CK; Choi SH; Yun H; Lee H; Park SH
Sci Rep; 2023 Apr; 13(1):6761. PubMed ID: 37185778
[TBL] [Abstract] [Full Text] [Related]
3. circMMD reduction following tumor treating fields inhibits glioblastoma progression through fubp1/FIR/DVL1 and miR-15b-5p/FZD6 signaling.
Xu S; Luo C; Chen D; Tang L; Cheng Q; Chen L; Liu Z
J Exp Clin Cancer Res; 2023 Mar; 42(1):64. PubMed ID: 36932454
[TBL] [Abstract] [Full Text] [Related]
4. Targeted DNA sequencing to identify genetic aberrations in glioblastoma that underlie venous thromboembolism; a cohort study.
Kapteijn MY; Kaptein FHJ; Stals MAM; Klaase EE; García-Ortiz I; van Eijk R; Ruano D; van Duinen SG; Cannegieter SC; Taphoorn MJB; Dirven L; Koekkoek JAF; Klok FA; Versteeg HH; Buijs JT
Thromb Res; 2023 Jan; 221():10-18. PubMed ID: 36435047
[TBL] [Abstract] [Full Text] [Related]
5. The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma.
Wang W; Lu Z; Wang M; Liu Z; Wu B; Yang C; Huan H; Gong P
Front Immunol; 2022; 13():998236. PubMed ID: 36110851
[TBL] [Abstract] [Full Text] [Related]
6. Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens.
Pallavajjala A; Haley L; Stinnett V; Adams E; Pallavajjala R; Huang J; Morsberger L; Hardy M; Long P; Gocke CD; Eshleman JR; Rodriguez FJ; Zou YS
Hum Pathol; 2022 Aug; 126():63-76. PubMed ID: 35561840
[TBL] [Abstract] [Full Text] [Related]
7. Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma.
Fleming JL; Pugh SL; Fisher BJ; Lesser GJ; Macdonald DR; Bell EH; McElroy JP; Becker AP; Timmers CD; Aldape KD; Rogers CL; Doyle TJ; Werner-Wasik M; Bahary JP; Yu HM; D'Souza DP; Laack NN; Sneed PK; Kwok Y; Won M; Mehta MP; Chakravarti A
JCO Precis Oncol; 2021; 5():. PubMed ID: 34589661
[TBL] [Abstract] [Full Text] [Related]
8. fubp1 promotes neuroblastoma proliferation via enhancing glycolysis-a new possible marker of malignancy for neuroblastoma.
Jiang P; Huang M; Qi W; Wang F; Yang T; Gao T; Luo C; Deng J; Yang Z; Zhou T; Zou Y; Gao G; Yang X
J Exp Clin Cancer Res; 2019 Sep; 38(1):400. PubMed ID: 31511046
[TBL] [Abstract] [Full Text] [Related]
9. Highly accelerated, model-free diffusion tensor MRI reconstruction using neural networks.
Aliotta E; Nourzadeh H; Sanders J; Muller D; Ennis DB
Med Phys; 2019 Apr; 46(4):1581-1591. PubMed ID: 30677141
[TBL] [Abstract] [Full Text] [Related]
10. Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics.
Synhaeve NE; van den Bent MJ; French PJ; Dinjens WNM; Atmodimedjo PN; Kros JM; Verdijk R; Dirven CMF; Dubbink HJ
Acta Neuropathol Commun; 2018 Nov; 6(1):126. PubMed ID: 30470264
[TBL] [Abstract] [Full Text] [Related]
11. Granular cell astrocytoma: an aggressive IDH-wildtype diffuse glioma with molecular genetic features of primary glioblastoma.
Vizcaino MA; Palsgrove DN; Yuan M; Giannini C; Cabrera-Aldana EE; Pallavajjala A; Burger PC; Rodriguez FJ
Brain Pathol; 2019 Mar; 29(2):193-204. PubMed ID: 30222900
[TBL] [Abstract] [Full Text] [Related]
12. EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients.
Zhang L; Liu Y; Wang M; Wu Z; Li N; Zhang J; Yang C
J Mol Cell Biol; 2017 Dec; 9(6):477-488. PubMed ID: 29272522
[TBL] [Abstract] [Full Text] [Related]
13. Cancer vaccines using supramolecular hydrogels of NSAID-modified peptides as adjuvants abolish tumorigenesis.
Wang Z; Liang C; Shi F; He T; Gong C; Wang L; Yang Z
Nanoscale; 2017 Sep; 9(37):14058-14064. PubMed ID: 28895610
[TBL] [Abstract] [Full Text] [Related]
14. CT follow-up in patients with neuroendocrine tumors (NETs): combined radiation and contrast dose reduction.
Böning G; Kahn JF; Kaul D; Rotzinger R; Freyhardt P; Pavel M; Streitparth F
Acta Radiol; 2018 May; 59(5):517-526. PubMed ID: 28786299
[TBL] [Abstract] [Full Text] [Related]
15. Expression of far upstream element-binding protein 1 correlates with c-Myc expression in sacral chordomas and is associated with tumor progression and poor prognosis.
Wen H; Ma H; Li P; Zheng J; Yu Y; Lv G
Biochem Biophys Res Commun; 2017 Sep; 491(4):1047-1054. PubMed ID: 28780352
[TBL] [Abstract] [Full Text] [Related]
16. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.
Thomas AA; Abrey LE; Terziev R; Raizer J; Martinez NL; Forsyth P; Paleologos N; Matasar M; Sauter CS; Moskowitz C; Nimer SD; DeAngelis LM; Kaley T; Grimm S; Louis DN; Cairncross JG; Panageas KS; Briggs S; Faivre G; Mohile NA; Mehta J; Jonsson P; Chakravarty D; Gao J; Schultz N; Brennan CW; Huse JT; Omuro A
Neuro Oncol; 2017 Oct; 19(10):1380-1390. PubMed ID: 28472509
[TBL] [Abstract] [Full Text] [Related]
17. Genetic landscape of extreme responders with anaplastic oligodendroglioma.
Holdhoff M; Cairncross GJ; Kollmeyer TM; Zhang M; Zhang P; Mehta MP; Werner-Wasik M; Souhami L; Bahary JP; Kwok Y; Hartford AC; Chakravarti A; Yegnasubramanian S; Vogelstein B; Papadopoulos N; Kinzler K; Jenkins RB; Bettegowda C
Oncotarget; 2017 May; 8(22):35523-35531. PubMed ID: 28388591
[TBL] [Abstract] [Full Text] [Related]
18. Genetic and epigenetic stability of oligodendrogliomas at recurrence.
Aihara K; Mukasa A; Nagae G; Nomura M; Yamamoto S; Ueda H; Tatsuno K; Shibahara J; Takahashi M; Momose T; Tanaka S; Takayanagi S; Yanagisawa S; Nejo T; Takahashi S; Omata M; Otani R; Saito K; Narita Y; Nagane M; Nishikawa R; Ueki K; Aburatani H; Saito N
Acta Neuropathol Commun; 2017 Mar; 5(1):18. PubMed ID: 28270234
[TBL] [Abstract] [Full Text] [Related]
19. The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas.
Tanboon J; Williams EA; Louis DN
J Neuropathol Exp Neurol; 2016 Jan; 75(1):4-18. PubMed ID: 26671986
[TBL] [Abstract] [Full Text] [Related]
20. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and fubp1.
Cahill DP; Louis DN; Cairncross JG
CNS Oncol; 2015; 4(5):287-94. PubMed ID: 26545048
[TBL] [Abstract] [Full Text] [Related]
[Next]
